Alzheimer's disease (AD) affects 10% of people older than 65 and is characterized by a progressive loss of cognitive function with an abnormal accumulation of amyloid β (Aβ) plaques and neurofibrillary tangles (NFT) in the brain. Efforts to reduce brain Aβ plaques continue to be investigated as a therapeutic approach for AD. We report here development of dual targeting agents with affinity for Aβ plaque/P-glycoprotein (Pgp) and Aβ plaque/α4β2* nicotinic acetylcholine receptors (nAChR). These novel dual agents may be able to efflux Aβ plaques via the paravascular (glymphatic) pathways. Ferulic acid (FA), ferulic acid ethyl ester (FAEE), and curcumin (CUR) were used for Aβ plaques, fexofenadine (FEX) was used as substrate for Pgp and nifrolidine (NIF) was used for α4β2* nAChRs. Aβ plaque/α4β2* nAChR dual agent, FA-NIF (GKS-007) exhibited IC 50 = 3-6 nM for α4β2* nAChRs in [ Graphical Abstract
Introduction
Alzheimer's disease (AD) is a neurodegenerative disease characterized by the accumulation of β-amyloid plaques (or senile plaques, SP) and neurofibrillary tangles (NFT) in the brain (Braak and Braak 1991) . Over the last few years efforts on diagnostic methods for plaques and more recently on NFT using positron emission tomography (PET) have made significant progress (Ariza et al. 2015) . With increasing efforts to find treatments and cure for AD, imaging plaques and NFT can contribute to the diagnosis and clinical management of AD (Barten and Albright 2008; Moghbel et al. 2012) . Emphasis is now on finding improved treatment strategies for AD. Currently, the only FDA approved drugs for AD treatment include acetylcholinesterase inhibitors (AChEI), such as donepezil, which may be supplemented with memantine (or Namenda) (#1 in Table 1 ). These drugs lessen symptoms of memory loss and confusion.
Reduction in the accumulation of amyloid β (Aβ) plaques and NFT continues to be investigated as therapeutic approaches for AD (Tampellini 2015; Venigalla et al. 2016) . Although, the NFT hypothesis is being sought after as a better indicator of clinical AD, Aβ plaque is still being pursued and efforts have been made to remove Aβ plaques in AD patients using antibodies (Salloway et al. 2014; Doody et al. 2014) . Current approaches underway as AD treatments involve attempts to decrease the plaque load in the brain either by removal of the Aβ plaques (using antibodies, curcumin (CUR) analogs and ultrasound) or decrease the production (using secretase inhibitors) of the Aβ plaques in the brain (Table 1) . Large clinical trials were carried out with anti-amyloid monoclonal antibodies, bapineuzumab (#2 Table 1 ; Salloway et al. 2014 ) and solanezumab (#3 Table 1 ; Doody et al. 2014; Siemers et al. 2016 ). Both of these trials did not improve clinical outcome and importantly the Aβ plaque load (measured by PET imaging) did not change significantly before and after antibody treatment. A different approach currently underway is to reduce the production of Aβ peptide by inhibition of the two secretases enzymes (γ-and β-), which cleave the amyloid precursor protein (APP; #4 Table 1 ). The γ-secretase inhibitors have an adverse effect on notch signaling pathway and were therefore not found to be suitable for further development. Development of β-secretase inhibitors are being pursued (Filser et al. 2015) , although some of them have been discontinued due to liver toxicity (Vassar 2014) . The natural product CUR and its analogs continue to be investigated for their anti-inflammatory and antiamyloidogenic properties (#5 Table 1 ; Hu et al. 2015; Gerenu et al. 2015) but concerns remain about efficacy in humans and brain bioavailability. Transgenic mice have considerably accelerated the understanding of the mechanisms of neurodegeneration underlying AD and development of therapeutics that may slow, halt, and potentially reverse AD. Immunization with fibrillar Aβ in young transgenic mice overexpressing mutant human APP can prevent subsequent plaque development (Schenk et al. 1999) . A number of therapeutic agents have been tested, such as nonsteroidal anti-inflammatory drugs, antioxidants, and statins in transgenic mice. Although, they provide insights on AD treatment, translation to humans has not occurred. More recently, scanning ultrasound was repeatedly used on the mouse brain to make the blood-brain barrier (BBB) leaky for Aβ removal (#6 Table 1 ; Leinenga and Gotz 2015) . Adaptation of this method to human use may pose a challenge. No efforts to remove Tau products from the brain have been made to the best of our knowledge.
Our overall goal is to develop dual targeting agents consisting of an Aβ plaque target agent that will be linked to a second target agent to assist in removal of the plaque from the brain and surrounding vasculature (Fig. 1) . Pglycoprotein (Pgp) is known to efflux macromolecules across the BBB and blood-cerebrospinal fluid barrier (BCSF; Jessen et al. 2015) . One specific objective is to develop and evaluate dual targeting agents with substrate affinity for Pgp and high affinity for Aβ plaque (Pgp-Aβ-binding molecule) that may be able to bind to Aβ and be effluxed out of the brain by Pgp using the paravascular (or glymphatic) pathways and olfactory lymphatic pathways ( Fig. 1b ; Bacyinski et al. 2017; Krishnamurthy et al. 2014) . In order to obtain a suitable dual Pgp-Aβ-binding agent, three features will be incorporated: (1) use ferulic acid (FA) 2 and CUR 3 as Aβ-binding agents; (2) Use fexofenadine (FEX) 4 (Tahara et al. 2005) as the substrate for Pgp; (3) use a linker 1-amino-4-butanol to connect the two targeting molecules. Ferulic acid ethyl ester (FAEE) and FA (1 and 2, Fig. 2 ), which are hemi-analogs of CUR 3 have all been reported to have anti-amyloidogenic properties.
The second approach is anchoring Aβ plaque clearing agents using neuronal α4β2* nicotinic acetylcholine receptors (nAChRs) and thus prolong their residence time in specific brain regions (Fig. 1d) . The α4β2* nAChRs receptors are involved in learning and memory and have been implicated in human neurodegeneration, including Alzheimer's disease, Parkinson's disease (Posadas et al. 2013) . The α4β2* nAChRs are localized in frontal cortex, cingulate, temporal cortex, subiculum, and parts of the hippocampus, all of which are known to have significant amounts of Aβ plaques in AD patients. We have previously prepared fluoroalkyl derivatives such as nifrolidine (NIF) 5 as radioligands for α4β2* receptors (Chattopadhyay et al. 2005; Pichika et al. 2011 Pichika et al. , 2013 . Derivatization of the 3-carbon chain at the 5-position in NIF does not adversely affect their binding to the α4β2* nAChRs as reported in our recent work for fluorescent probes containing large fluorophores at the 5-position ). Thus, NIF derivative was coupled to FAEE and FA to provide the second class of dual targeting agents.
Thus, in this paper we report the following: (1) synthesis of dual Aβ-Pgp-binding agent using FEX (Fig. 2) as the substrate for Pgp (Tahara et al. 2005 ) and FA and CUR as Aβ-binding agents; (2) synthesis of dual Aβ-α4β2* nAChR- 
Materials and methods

General methods
All chemicals and solvents were of analytical or high performance liquid chromatography (HPLC) grade from Aldrich Chemical Co. and Fisher Scientific. Electrospray mass spectra were obtained on a Model 7250 mass spectrometer (Micromass LCT). Proton nuclear magnetic resonance (NMR) spectra were recorded on a Bruker OMEGA 600 MHz spectrometer. Analytical thin layer chromatography (TLC) was carried out on silica coated plates (Baker-Flex, Phillipsburg, NJ). Chromatographic separations were carried out on preparative TLC (silica gel GF 20 × 20 cm 2000 micron thick; Alltech Assoc. Inc., Deerfield, IL) or silica gel flash columns or semi-preparative reverse-phase columns using the Gilson HPLC systems. Rat and human postmortem brain slices were obtained on a Leica 1850 cryotome. [
3 H]Cytisine and [ 3 H]PIB autoradiographic studies were carried out by exposing tissue samples on storage phosphor screens. The apposed phosphor screens were read and analyzed by OptiQuant acquisition and analysis program of the Cyclone Storage Phosphor System (Packard Instruments Co., Boston, MA).
All rodent studies were approved by the Institutional Animal Care and Use Committee (IACUC) of the University of California, Irvine. All human postmortem brain tissue studies were approved by the Institutional Biosafety Committee of the University of California, Irvine.
Synthesis
Ethyl 3-methoxy-4-(1′-N-BOC-aminobutyryloxy)cinnamate 6
Ethyl ferulate 1 (45 mg; 0.2 mmol) was dissolved in tetrahydrofuran (1 mL). To this solution, potassium tert-butoxide (50 mg) was added at room temperature and stirred for 15 min followed by the addition of N-BOC-4-bromobutan-1-amine (51 mg; 0.2 mmol) was added. The solution turned bright yellow and was stirred at room temperature for 24 h. The reaction was then washed with saturated sodium bicarbonate and extracted with dichloromethane. The organic extract was purified on preparative silica gel TLC using 9:1 dichloromethane-methanol to provide 37 mg (~45% yield) of pure 6. Mass spectra (m/z, %): Ethyl 3-methoxy-4-(1′-aminobutyryloxy)cinnamate 7
The N-BOC derivative 6 (20 mg; 50 μmol) was taken in dichloromethane (2 mL) into which 0.1 mL of 
FEX-(3-methoxy-4-(1′-aminobutyryloxy)cinnamic acid 8
FEX 4 (13 mg; 26 μmol) was dissolved in acetonitrile (2 mL). To this solution, amine 7 (10 mg; 34 μmol) was added followed by addition of BOP (15 mg; 34 μmol) along with 0.1 mL triethylamine. The mixture was stirred at room temperature for 24 h. The reaction solvent was removed and the residue was taken up in dichloromethane and washed with saturated sodium bicarbonate. The organic layer was dried and purified on preparative silica gel TLC using 9:1 dichloromethane-methanol to provide 11 mg (~54% yield) of pure amide in >95%. Mass spectra (m/z, %):
). This amide was taken in methanol (0.5 mL) into which 0.5 mL of 1 N sodium hydroxide was added. The reaction mixture was heated at 60 o C for 30 min. The reaction was quenched with water and extracted with dichloromethane. The organic extract was purified on preparative silica gel TLC using 1:1 dichloromethane-methanol to provide pure 8. Mass spectra (m/z, %): 
FEX curcuminate 9
FEX 4 (26.9 mg; 54 μmol) was dissolved in acetonitrile (2 mL). To this solution, CUR 3 (18.6 mg; 50 μmol) was added followed by addition of BOP (23 mg; 52 μmol) along with 0.1 mL triethylamine. The solution turned bright orange and was stirred at room temperature for 24 h. The reaction solvent was removed and the residue was taken up in dichloromethane and washed with saturated sodium bicarbonate. The organic layer was dried and purified on preparative silica gel TLC using 9:1 dichloromethanemethanol to provide pure 9 in >90% purity with an approximate yield of 25%. Mass spectra (m/z, %): 5-(3′-Ethyl 3-methoxy-4-propyloxycinnamate)-3-(1-BOC-2-(S)-pyrrolidinylmethoxy)pyridine 11 5-(3-Tosyloxypropyl)-3-(1-BOC-2-(S)-pyrrolidinylmethoxy)pyridine 10 (34 mg, 70 μmol; prepared previously (Chattopadhyay et al. 2005) was reacted with ethyl ferulate 1 (20 mg, 90 μmol) in dimethylformamide (1 mL) in the presence of potassium tert-butoxide (12 mg). The reaction was heated for 24 h at 100°C and subsequently water (2 mL) was added and the mixture was extracted with dichloromethane. The dichloromethane extract was purified on preparative silica gel TLC using 9:1 dichloromethanemethanol to provide 11 in >95% purity and a yield of~30%. 
5-(3′-Ethyl 3-methoxy-4-propyloxycinnamate)-3-(2-(S)-pyrrolidinylmethoxy)pyridine 12
The substituted ethyl ferulate 11 (5 mg; 9 μmol) was taken in dichloromethane (1 mL) into which 0.1 mL of TFA was added. The reaction was stirred at room temperature for 24 h. The reaction was quenched with saturated sodium bicarbonate and extracted with dichloromethane. The organic extract was purified on preparative silica gel TLC using 9:1 dichloromethane-methanol to provide pure 12. 
5-(3-methoxy-4-propyloxycinnamate)-3-(2-(S)-pyrrolidinylmethoxy)pyridine 13
Ether 12 (4 mg; 10 μmol) was taken in methanol (0.5 mL) into which 0.5 mL of 1 N sodium hydroxide was added. The reaction mixture was heated at 60°C for 30 min. The reaction was quenched with water and extracted with dichloromethane. The organic extract was purified on preparative silica gel TLC using 1:1 dichloromethane-methanol to provide pure 13. 
In vitro studies
All animal studies were approved by the IACUC of the University of California-Irvine. Ex vivo rat brain slices were prepared at 10 µm thick using a 
Results
Synthesis
For Pgp and Aβ amyloid dual agent, two different approaches were taken. Figure 3 shows derivatization of FAEE with the 4-carbon linker. In the presence of base, the phenolate of FAEE 1 was reacted with N-BOC-1-bromo-4-butylamine to provide 6 in 45% yield. Removal of the N-BOC protecting group using TFA resulted in the corresponding amine 7 in 95% yields. FEX 4 was coupled to the amine 7 using BOP to form the amide derivative of FAEE. Base hydrolysis of this amide-ester resulted in the FA derivative 8 in 50-60% yields. Fig. 3 Synthesis of Aβ-Pgp agents using linker. O-alkylation of FAEE 1 with N-BOC bromobutylamine to 6. Deprotection of N-BOC 6 with TFA, trifluoroacetic acid for 7. Amide formation with FEX 4 and 7 using BOP, benzotriazol-1-yloxy)tris(dimethylamino) phosphonium hexafluorophosphate followed by base hydrolysis to provide 8
The second approach for Pgp and Aβ amyloid dual agent is shown in Fig. 4 . FEX 4 was directly coupled to CUR 3 using BOP to form the FEX-CUR derivative 9 in an ester linkage. This dual agent ester was obtained in moderate yields. Potential steric effects from the adjacent gemdimethyl group may have affected the yields. The use of the 4-carbon linker may help in increasing the coupling yield, with the formation of an ether-amide link between FEX and CUR.
To obtain dual agent for α4β2* nAChRs and Aβ amyloid, the N-BOC tosylate 10 was used, which was synthesized previously. 21 Coupling of the N-BOC tosylate 10 with FAEE 1 was carried out using nucleophilic substitution reaction by the phenolate of FAEE shown in Fig. 5 . The ether 11 was obtained in 30% yields. Formation of the ether under Mitsunobu reaction conditions using DIAD/Ph 3 P as the coupling agent did not provide good yields. Removal of the N-BOC protecting group using TFA resulted in GKS-006 12 in 85-90% yield. Base hydrolysis of the ethyl ester in GKS-006 12 provided GKS-007 13 in 80% isolated yields. The purified GKS-006 and GKS-007 were used for in vitro studies.
Aβ plaque binding
The Aβ plaque-Pgp dual agents, KD-003 and CUR-FEX were tested for binding to Aβ amyloid plaques in human postmortem AD brain frontal cortex slices that were labeled with [ ]PIB labeling of human AD frontal cortex section, which was greater in the gray matter (GM) regions compared to white matter (WM) regions with GM/WM ratio of approx. 3. In the presence of FA (10 μM) both GM and WM showed higher levels of [ 3 H]PIB with a GM/WM ratio of 2 (Fig. 6b) . The dual agent KD-003 (Fig. 6c, 10 μM) also showed higher levels of [ 3 H]PIB with GM/WM ratio of 2.4. CUR (10 μM), known to have a high affinity for Aβ amyloid showed the lowest GM/WM ratio of 1.5 (Fig. 6e,  g ). The dual agent of CUR, CUR-FEX (10 μM) showed lower binding of [ 3 H]PIB (Fig. 6d, f) , with GM/WM ratio reduction to 1.96 as seen in Fig. 6g .
The Aβ plaque-α4β2* nAChR dual agent was tested for binding to Aβ amyloid plaques in human postmortem AD brain frontal cortex slices labeled with [ (Fig. 7a) , which was greater in the GM regions compared to WM regions with GM/WM ratio of~2. In the presence of 4-methylamino-4'-N,N-dimethylaminoazobenzene (TAZA) (1 μM), which is known to bind to Aβ amyloid plaques with high affinity (Pan et al. 2016 ), significant displacement of [ 3 H]PIB occurred from the GM regions (Fig. 7c) , with GM/WM ratio reducing to 1:3. Unlike the effects of TAZA, FA (1 μM) did not significantly affect the binding of [ (Fig. 7d) , with GM/WM ratio of~2, which was similar to that of the control (Fig. 7b) . Similarly the Aβ plaque-α4β2* nAChR dual agent, Fig. 4 Curcumin ester synthesis of Aβ-Pgp agent. Esterification of CUR 3 and FEX 4 using BOP. Energy-minimized models comparing the dual agent, CUR-FEX 9 with CUR 3 and FEX 4 Fig. 5 Ferulic acid ether synthesis of Aβ-α4β2* agents. Reaction of substituted tosylate 10 and FAEE 1 (base, THF, tetrahydrofuran) to provide ether 11. Deprotection of N-BOC 11 with TFA for GKS-006 12 and base hydrolysis of 12 to provide GKS-007 13. Energyminimized models comparing the dual agent, FA-NIF (GKS-007) 13 with FA 2 and NIF 5 (Fig. 7e) , but there was no significant GM/WM ratio reduction as seen in Fig. 7g .
Nicotinic receptor binding
The Aβ plaque-α4β2* nAChR dual agents were tested for their affinity to the α4β2* nAChRs using rat brain slices labeled with [ 3 H]cytisine. Figure 8 shows [
3 H]cytisine labeling of rat brain regions of thalamus, frontal cortex, striatum, subiculum, and cerebellum as previously reported . Displacement of significant amounts of [ 3 H]cytisine was observed by 100 nM of GKS-006 (Fig. 8c) and 100 nM GKS-007 (Fig. 8d) . Three brain regions analyzed included thalamus, frontal cortex, and subiculum. With increasing concentration of GKS-006 (Fig. 8e, g ) and GKS-007 (Fig. 8f, h) 
Discussion
There is an increasing evidence of the presence of ventricular clearance pathways, such as the paravascular (or also referred as glymphatic) pathway and olfactory lymphatic pathway, which may be involved in clearing macromolecules from the brain (Jessen et al. 2015; Bacyinski et al. 2017) . Specific proteins, such as aquoporin4, have been identified that may play a critical role in the movement of water containing macromolecules (Jessen et al. 2015) . Insufficient clearance of macromolecules, such as Aβ, results in formation of Aβ fibrils and plaques in the brain. Downregulation of Pgp has been reported in AD (Bartels 2011; Pahnke et al. 2008 ) and upregulation of Pgp using rifampicin and caffeine were found to increase clearance of Aβ from the brain (Qosa et al. 2012) . In normal human plasma a soluble form of lipoprotein receptor related protein (LRP1) is a major endogenous brain Aβ "sinker" that sequesters up to 90% of plasma Aβ peptides. In AD the levels and capacity of LRP1 are reduced that increases free Aβ fraction in plasma. This in turn may increase the brain Aβ burden through decreased Aβ efflux and/or increased Aβ influx across the BBB (Deane et al. 2009 ). To what extent these efflux pathways along with Pgp may be involved in removal of the larger Aβ products (oligomers, fibrils, and plaques) from the brain is currently not known.
Thus, our first approach was to assist and enhance the ability of Pgp to increase Aβ efflux. Several substrates and inhibitors have been well characterized for Pgp (Syvanen and Eriksson 2013) . FEX is an antihistamine used for allergies and is a Pgp substrate (Tahara et al. 2005; Zhao et al. 2009 ). The presence of the carboxylic acid functional group enables its easier derivatization compared to other Pgp substrates (Fig. 2) . Modification of the carboxylic acid end of FEX may not have major detrimental effects on its interaction with Pgp as a substrate. The carboxylic acid group in FEX was used to form either an amide bond to attach a 4-carbon chain linker to FA or alternatively it was attached directly to CUR in a phenolic ester linkage. Energy-minimized structures of FEX, CUR, and the dual agent CUR-FEX exhibited similar backbone structures suggestive of maintenance of binding properties of CUR to Aβ amyloid (Fig. 4) . FA, FAEE, and CUR have all been reported to bind and interact with Aβ amyloid plaques and help in the dissolution/disaggregation of the Aβ plaques (Mancuso and Santangelo 2014; Sultana 2012; Sgarbossa et al. 2015; Yan et al. 2013) . In order to enhance this property of dissolution/disaggregation of the Aβ plaques by FAEE and FA, our second strategy involved increasing the brain retention time of these agents by anchoring them to a secondary target. Using our previously developed PET imaging agent [ 18 F]NIF, we recently reported two fluorescent probes, nifrodansyl, and nifrofam with nanomolar affinities for α4β2 * nAChRs . Nifrofam labeling was observed in α4β2 * nAChR-expressing HEK cells and was upregulated by nicotine exposure. Based on these findings, we used a similar approach in derivatizing NIF using a ether linkage (as opposed to an amide linkage in the case of nifrofam) with FAEE and FA. Energy-minimized structures of NIF, FA, and the dual agent FA-NIF (GKS-007) shows retention of primary-binding features to α4β2 * nAChR (Fig. 5 ). This was confirmed by the high affinity measured for both GKS-006 and GKS-007 at the α4β2 * nAChR sites in rat brain slices. CUR had a significant displacement effect on the binding of [
3 H]PIB to the Aβ plaques in human frontal cortex (Fig.  6 ). This is consistent with the binding affinity for Aβ plaques/fibrils reported for CUR (Ryu et al. 2006) . Although, binding of [ (Fig. 7) was greater than observed by CUR and is consistent with our previous findings of the high affinity of TAZA for Aβ plaques (Pan et al. 2016 (Bacyinski et al. 2017; Deane et al. 2009 ). Crystal structure of Pgp at 3.8 Å revealed an internal cavity of ∼6000 Å cubed with a 30 Å separation of the two nucleotide-binding domains. Two additional Pgp structures with cyclic peptide inhibitors demonstrate distinct drug-binding sites in the internal cavity capable of stereoselectivity that is based on hydrophobic and aromatic interactions (Aller et al. 2009 ). Based on this size, the Pgp pore may not directly efflux large Aβ products, but we anticipate that Aβ-Pgp dual agents may assist in the bringing Aβ products in the vicinity of BBB and BCSF in order for the glymphatic pathway to efflux the macromolecules. Additionally if smaller fragments of Aβ fibrils are formed by the action of CUR containing dual agent (Garcia-Alloza et al. 2007 ), they may be taken across the BBB more efficiently.
Further evaluation will require measurement of Pgp substrate selectivity of the Aβ-Pgp dual agents; preparation of the higher affinity CUR derivative, CUR-NIF so that it has a high affinity for both the α4β2 * nAChRs and Aβ plaques. In vivo studies in transgenic mice (e.g., Coleman et al. 2017; Pi et al. 2012 ) are planned with both classes of dual agents in order to evaluate stability, BBB permeability and interaction with the target sites for α4β2 * nAChRs , Aβ plaques (Brendel et al. 2015) , and Pgp (Vlaming et al. 2015) .
Conclusions
We have successfully developed two classes of dual targeting agents, Aβ plaque/Pgp and Aβ plaque/α4β2* nAChR in an effort to provide novel approaches to help remove Aβ plaques from the AD brain. Preliminary findings show that both classes of compounds maintain affinity for their respective targets. Further in vitro and in vivo studies are needed to fully characterize them and validate their potential to bind to Aβ plaques, including fibrils in the brain and surrounding vasculature.
